Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Self-Inhaled vapor beat oral painkillers in the ER?

NCT ID NCT07742007

Symptom relief Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial asks whether inhaling methoxyflurane, a fast-acting pain reliever, can reduce pain more quickly than standard oral medications for adults arriving at the emergency department with non-traumatic pain. Participants with moderate to severe pain will be randomly assigned to receive either methoxyflurane or usual care, and the time to meaningful pain relief will be measured. The goal is to see if this inhaled option can offer faster relief for people waiting in the ER.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methoxyflurane (Penthrox), an inhaled analgesic self-administered under supervision
What this could lead to
If effective, methoxyflurane could offer a fast, non-opioid option for managing moderate to severe pain in emergency departments, potentially reducing wait times for relief.
What could go wrong
This is a phase 3 trial, but results are not yet known. Methoxyflurane may not prove superior to usual care, and it carries risks like any medication, including potential side effects or contraindications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 164 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult ≥ 18 years * Acute non-traumatic pain of moderate to severe intensity (VAS strictly greater than 39 mm) * Able to independently assess their pain using a VAS and to record it independently on paper. * Affiliated to a social security system * Having signed informed consent Exclusion Criteria: * Age \< 18 years * Contraindications to methoxyflurane as stated in the Summary of Product Characteristics: * Hypersensitivity to the active substance or to any other fluorinated anesthetic or to any excipient. * Malignant hyperthermia: known malignant hyperthermia or genetic predisposition. * History of serious adverse reactions (patient or relatives) after administration of inhaled anesthetics. * History of signs of liver injury after use of methoxyflurane or halogenated hydrocarbons. * Clinically significant renal impairment * Altered level of consciousness regardless of cause, including head trauma, drug or alcohol use * Clinical evidence of cardiovascular instability * Clinical evidence of respiratory depression * Hemodynamically unstable patient (SBP \< 100 mmHg, DBP \< 30 mmHg) * Patient having already received Methoxyflurane on the same day * Patient having taken analgesic treatment prior to emergency consultation within 4 hours of admission. * Pain ≤ 39 mm * Pregnant, breastfeeding. * Women of childbearing potential not using a highly effective method of contraception throughout the study. The absence of pregnancy must be confirmed by performing a pregnancy test. Patients who are unable to provide a urine sample at the time of inclusion will not be enrolled in the study. * Subject under legal protection * Patients currently within the exclusion period of another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pain management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Emergencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pain management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Hôpitaux de Tours - Urgences de l'Hôpital Trousseau

    Tours, CHRU de Tours, 37170, France

  • CHU d'Angers

    Angers, 49100, France

  • CHU d'Orléans

    Orléans, 45100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.